Data Elements 

​Scientific Steering Committee

​Publications

   
2018
Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network
  
Access to and Utilization of Sofsbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

   
Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network
   

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
 
   
Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
   
Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in the Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

    

2017
Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network


Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network
  

   
Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network


Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network                 
  
Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)  
 
Impact of treatment duration and ribavirin (RBV) addition on real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in select patient subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective data analyses from the Trio Network

   
Cure denied and cure delayed in Chronic Hepatitis C; monitoring non-start rates and increased time to start using real-world data from the TRIO Network


HCV Treatment Failure in the era of direct-acting antivirals (DAAs): Analyses of real-world data from the TRIO Network   
      

Drivers of Therapy Choice in Genotype 1 HCV: Analyses of real-world data from the TRIO Network
    

Real-world patterns of therapy utilization and outcomes in 8,049 HCV patients: data from the TRIO Network
    
   

2016
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients In the TRIO Network

Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network
    
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real-Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network
    

2015
Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network    
       
Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network
   
Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Evaluation of Access to Care in Patients Prescribed Sofosbuvir-containing Regimens; Data from the TRIO Network

Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network
    

   
Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
 
2014
Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network

Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network